All In Biotech

Drug Trial Radar · NCT03260894

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

Dec 7, 2017

Primary completion

Aug 22, 2018

Study completion Jun 4, 2025

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.

Conditions

  • Renal Cell Carcinoma (RCC)

Interventions

  • PembrolizumabDrug

    Pembrolizumab 200 mg administered intravenously every 3 weeks.

  • EpacadostatDrug

    Epacadostat 100 mg administered orally twice daily.

  • SunitinibDrug

    Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.

  • PazopanibDrug

    Pazopanib 800 mg administered orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)Time frame: up to approximately 8 months

Locations

140 sites in 20 countries. Site status is shown where the registry gives one.

  • Pinnacle Oncology Hematology

    Scottsdale, Arizona

  • Scottsdale Healthcare

    Scottsdale, Arizona

  • Arizona Oncology Associates PC- HOPE

    Tucson, Arizona

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UC Irvine Comprehensive Cancer Center/Chao Family Comprehensive Cancer Center

    Orange, California

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Woodlands Medical Specialists, PA

    Pensacola, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Atlanta Cancer Care - Conyers

    Conyers, Georgia

  • Northwest Georgia Oncology Centers Pc

    Marietta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Southeast Nebraska Hematology & Oncology Consultants, P.C.

    Lincoln, Nebraska

  • New York Oncology Hematology P.C

    Albany, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Willamette Valley Cancer Institute and Research Center

    Eugene, Oregon

  • University of Tennessee Erlanger Oncology & Hematology

    Chattanooga, Tennessee

  • The West Clinic, P.C.

    Germantown, Tennessee

  • US Oncology and Research

    The Woodlands, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    Roanoke, Virginia

  • Shenandoah Oncology, P.C.

    Winchester, Virginia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Canberra Hospital

    Garran, Australian Capital Territory, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Cabrini Health

    Malvern, Victoria, Australia

  • Centro Avancado de Tratamento Oncologico - CENANTRON -

    Belo Horizonte, Brazil

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Brazil

  • Centro de pesquisa Porto Alegre

    Porto Alegre, Florianopolis, Brazil

  • Fundacao Pio XII - Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Instituto do Cancer de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Hospital Sao Jose

    São Paulo, São Paulo, Brazil

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Kingston Health Sciences Centre - KGH Site

    Kingston, Ontario, Canada

  • Sunnybrook Health Sciences, Odette Cancer Centre

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.